COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, a digital health leader revolutionizing chronic care, today announced that the company’s 31st patent was granted on June 14, 2022, demonstrating the continued advancement of Welldoc’s first-in-class technology for comprehensive chronic condition management. Welldoc’s portfolio includes patents from the U.S. Patent and Trademark Office and IP Australia.
“The expansion of Welldoc’s IP portfolio to thirty-one patents for our platform reinforces our position as a pioneer in the development of digital health solutions for chronic care,” said Kevin McRaith, President and CEO of Welldoc. “Given the continued advancement in device technology and real-time data capabilities, there is an increased need for connected care solutions which aggregate, translate and visualize large sets of data into meaningful, personalized insights. Welldoc’s early seminal patent filings have enabled us to leverage and adapt our existing technology for use in these modern applications.”
These latest additions to Welldoc’s patent portfolio will support the advancement of the company’s technology designed to optimize clinical decision support across diabetes, hypertension, heart failure and behavioral health. Welldoc currently has patents granted in the U.S. and Australia, with applications pending in the U.S., Europe, Asia, Australia and Canada.
Welldoc’s flagship product, BlueStar®, is an FDA-cleared digital health platform that provides users with the personalized feedback needed to take control of their diabetes management. By analyzing historical data and decision patterns, BlueStar offers real-time coaching designed to shape behaviors including food, activity and medication use with the goal of improving users’ total health.
About Welldoc®
Welldoc®, a digital health leader revolutionizing chronic care, is integrating personalized, real-time and actionable insights into the daily lives of individuals living with chronic conditions, enabling improved health and outcomes. Welldoc’s comprehensive chronic care platform provides multi-condition support across diabetes, hypertension, heart failure and behavioral health. Welldoc’s flagship product, BlueStar®, an FDA-cleared digital health solution, guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. Welldoc partners with health plans, health systems and employers with the goal of extending care, improving health and reducing costs. For more information, visit www.welldoc.com. Follow us on LinkedIn and Twitter.
